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Mitochondrial dysfunction has been implicated in premature aging, age-related diseases, and tumor initiation and progression.
Alterations of the mitochondrial genome accumulate both in aging tissue and tumors. This paper describes our contemporary
view of mechanisms by which alterations of the mitochondrial genome contributes to the development of age- and tumor-related
pathological conditions. The mechanisms described encompass altered production of mitochondrial ROS, altered regulation
of the nuclear epigenome, aﬀected initiation of apoptosis, and a limiting eﬀect on the production of ribonucleotides and
deoxyribonucleotides.
1.Introduction
Mitochondria are semiautonomous organelles present in
almost all eukaryotic cells in quantities ranging from a single
copy to several thousands per cell. Important mitochondrial
functions include ATP production by oxidative phosphory-
lation, β-oxidation of fatty acids, and metabolism of amino
acids and lipids. Furthermore, mitochondria have a promi-
nent role in apoptosis initiation. The circular mitochondrial
DNA (mtDNA) is more susceptible to DNA damages in
comparison to nuclear DNA (nDNA). Importantly, mtDNA
molecules are not protected by histones, they are supported
with only rudimentary DNA repair and are localized in
close proximity to the electron transport chain (ETC),
which continuously generates oxidizing products known as
reactive oxygen species (ROS). Thus, the mutation rate of
mtDNA has been reported to be up to 15-fold higher than
observed for nDNA in response to DNA damaging agents
[1].
Mitochondrial dysfunction and especially dysfunctions
caused by mutations of the mtDNA have been implicated
with a wide range of age-related pathologies, including can-
cers, neurodegenerative diseases and, in general, processes
that regulate cellular and organismal aging. The mitochon-
drial genome encodes peptides essential for the function of
the ETC and production of ATP by oxidative phosphoryla-
tion. Electrons are primarily donated to the ETC from the
Krebs cycle, but other sources also contribute. The human
enzyme dihydroorotate dehydrogenase (DHODHase), an
integral part of the de novo synthesis of pyrimidines, is
coupled to the ETC [2, 3]. The activity of the enzyme is
dependent on its ability to transfer electrons to the ETC. ATP
is the primary product of oxidative phosphorylation, but
certain molecules of ROS are also generated continuously [4,
5]. At subtoxic concentrations, ROS has been demonstrated
to function as second messenger molecules proposed to
report oxygen availability for oxidative phosphorylation
and energetic yield, aﬀecting epigenetic marking of nDNA
and regulating nuclear transcription factors, kinases, and
phosphatases as reviewed by Weinberg and Chandel [6].
However, at increased levels, ROS induces oxidative damage
to lipids, proteins, RNA, and DNA.
Mutation of mtDNA has been correlated with aging and
cancer. Mutations of mtDNA that results in an aberrant
expression of mitochondrial encoded ETC subunits have
been demonstrated to impair the activity of the ETC
and be correlated with a decreased capacity for oxidative
phosphorylation [7, 8]. In turn, as will be reviewed, ETC
dysfunction has been demonstrated to aﬀect the production
ofATPandROS,altertheexpressionofseveralnucleargenes,
aﬀect the regulation of proteins, and disturb the synthesis
of cellular nucleotides. The focus of this paper is on the
immediate eﬀects of mtDNA alterations and their potential
role in premature aging and tumor progression.2 Journal of Aging Research
2. mtDNA FidelityIs Correlatedwith
Aging andCancer
The lifespan of both mice and aging human cultured
cells has been associated with decreases in the number of
mitochondria and changes of mitochondrial morphology
[9–11]. These alterations are accompanied by an accumula-
tion of mutations in the mtDNA [12–16]. Accordingly, an
age-related decline of mitochondrial capacity for oxidative
phosphorylation has been demonstrated in both human
skeletal muscle and rat hearts [7, 8, 17].
Increasing evidence suggests an important role of accu-
mulating mtDNA mutations in the pathogenesis of many
age-relatedneurodegenerativediseasesaswellasanumberof
age-related pathological alterations of heart, skeletal muscle,
and the vascular system [18–21]. A strong correlation
between the ﬁtness of mtDNA and age-related pathologies
have been demonstrated with the independent construction
of two mouse lines expressing mutated versions of the mito-
chondrial polymerase gamma. Both mouse lines developed a
mtDNA mutator phenotype, linking the increase of somatic
mtDNA mutations with symptoms of premature aging and
reduced lifespan [22, 23]. Furthermore, in a longevity study,
human life length could be associated with the life length of
the mother but not the father, suggesting an inﬂuence of the
maternal inherited mitochondrial genome [24, 25].
Warburg formulated a relationship between mitochon-
dria and cancer with the discovery that most tumors relied
on ATP production by glycolysis rather than oxidative phos-
phorylation[26].AlterationsofmtDNAhavebeencorrelated
with tumor progression and have been reported in a variety
of cancers including ovarian, thyroid, salivary, kidney, liver,
lung,colon,gastric,brain,bladder,headandneck,andbreast
cancers [27–29]. Reported alterations include point muta-
tions,deletions,anddepletions.AlterationsofmtDNAmight
merely be a consequence of tumor progression, however,
it has been demonstrated that the invasive phenotype of
human cells depleted of mtDNA can be reversed by rein-
troducing exogenous wild-type mitochondria [30, 31]. Fur-
thermore,constructionofa cybridcellline ofprostatecancer
cells harboring speciﬁc mtDNA mutations has in nude mice
been demonstrated to have a growth advantage over cybrids
of prostate cells with functional mtDNA [32, 33]. As a result,
cybridcancercellswithmtDNAmutationshavethepotential
of forming a tumor 7-fold larger than cybrid cancer cells
with functional mtDNA [32]. Together these indications
suggest that mtDNA alteration is directly involved in tumor
progression and not merely a consequence of it.
3. Accumulation of mtDNA Mutations
The circular human mtDNA are present in several copies
in each mitochondrion. The mtDNA molecule consists of
16539 base pairs that constitute 37 genes encoding 22 tRNAs,
2 rRNAs, and 13 polypeptides. The encoded polypeptides
comprise few but essential subunits of the ETC and ATP
synthase [34, 35]. The ETC maintains an electrochemical
potential gradient between the intermembrane space and the
matrix of the mitochondria. This gradient is utilized by the
ATP synthase to generate ATP by oxidative phosphorylation.
The ETC consists of four membrane-bound enzyme com-
plexes (complex I–IV), two electron carriers (ubiquinon and
cytochrome c), and is located in the inner membrane of the
mitochondria. Mutations in mtDNA aﬀect the function of
the ETC, the electrochemical gradient, and the generation of
ATP by oxidative phosphorylation. Furthermore, mutations
of mtDNA can result in an elevated production of ROS.
Somatic mutations in the mtDNA have been suggested
to accumulate during the life span of humans. Accordingly, it
hasbeendemonstratedthatbrain,muscle,heart,andskeletal
muscle of aging humans harbor an increased mutational
load of the mitochondrial genome when compared to cor-
responding tissues of young [5, 8, 12, 36]. The age-correlated
accumulation of mtDNA mutations has been proposed to be
the cumulative result of a mitochondrial vicious circle and
a preferential accumulation of speciﬁc mtDNA mutations
[37]. According to the theory of a mitochondrial vicious
circle, mutations in either nuclear or mitochondrial genes
encoding subunits of the ETC will impair electron transfer
leading to increased ROS production [38]. Consequent
oxidative damage to mtDNA induces alterations of the
mtDNA-encoded polypeptides of the ETC leading to further
ROS production, thus establishing a vicious circle resulting
in an accumulation of mtDNA mutations.
In a variety of diseased and aging tissue, cells of the
tissue are a mosaic of cells containing non-mutated mtDNA
molecules and cells containing mutated mtDNA molecules
[16, 36, 39, 40]. Cells containing mutated mtDNA are often
homoplasmic indicating thatthemutations arenot theresult
of random oxidative damages from mitochondrial ROS.
Rather, these mutations are the consequence of a preferential
accumulation of a speciﬁc mutated mtDNA molecule, which
has become the predominant species within a single cell.
The mechanism of this selection is unknown, however it has
been hypothesized that mitochondria containing mutated
mtDNA causing a reduced respiratory function will have a
lower production of ROS and consequently have a lower
risk of oxidative damage of the mitochondrial membrane.
Mitochondria with a reduced respiratory function will
thereforehavealowerriskofsuﬀeringlysosomaldegradation
allowing the aﬀected mitochondria to populate the cell [41].
In contrast, in Silico models have demonstrated the potential
of a single mutated mtDNA molecule to clonally expand in
postmitotic cells without the requirement of any types of
selection but rather through random genetic drift in a pool
of replicating mtDNA molecules [42]. Age-related accumu-
lation of mtDNA mutations is therefore likely either a result
of a mitochondrial vicious circle, preferential accumulation
of speciﬁc mtDNA mutations, or the cumulative outcome of
both factors.
4. Mitochondria-ProducedROS Can Damage
Cellular Components
More than 90% of cellular oxygen uptake is utilized in the
process of oxidative phosphorylation which continuouslyJournal of Aging Research 3
generates ROS such as superoxide anions (O
·−
2 ), hydrogen
peroxide (H2O2), and hydroxyl radicals (OH·), [5, 43]. ROS
are generated to an extent of 1–4% of the oxygen consumed
by the mitochondria [4, 5]. Complex I and especially com-
plex III are the prime sites for electron leakage to molecular
oxygen yielding O
·−
2 [44, 45]. The production of ROS is
inversely correlated with the rate of electron transport,
increasing exponentially when complex I or III are impaired
[46]. The main mediator of electron leakage is the reduced
form of ubiquinone, ubiquinol, which is able to reduce
molecular oxygen [47]. In order to neutralize the produced
ROS, a number of antioxidant defenses are active within the
mitochondria. O
·−
2 is neutralized by intramitochondrial Mn
superoxide dismutase (SOD2) catalyzing the formation of
H2O2. The latter either diﬀuses out of the mitochondria or
is inactivated by reaction with glutathione catalyzed by glu-
tathione peroxidase [48–50]. If the amount of produced ROS
exceeds the capacity of SOD2 and glutathione peroxidase,
O
·−
2 and H2O2 levels will rise. In the presence of transition
metals, such as iron or copper, highly reactive OH· can be
produced by Haber-Weiss or Fenton reactions. OH· can in
turngiverisetoaplethoraofROS,whichcanfurtherdamage
proteins, lipids, and DNA [43, 51, 52].
The mitochondrial production of ROS is an essential
component of the free radical theory of aging formulated
by Harman [53–55]. According to the theory, mitochondria-
produced ROS induces oxidative damage to lipids, proteins,
and DNA in mitochondria and potentially in nucleus.
Consequently, ROS production is considered one of the
causes of aging and age-related pathologies [38, 56–58]
and a contributing factor in the formation of cancers [59,
60]. In support of this theory it has been demonstrated
that inactivation of the Sod2 gene in mice lead to a 2-3-
fold increase of oxidative damages of the nuclear DNA in
heart and brain tissue when compared to mice expressing
SOD2 [5]. Furthermore, it has been demonstrated that
an overexpression of a human catalase targeted for the
mitochondria, prolonged median and maximal lifespan of
mice by approximately 20% and enhanced exercise perfor-
mance when compared to wild-type littermates [61, 62].
Mice overexpressing the mitochondrial targeted catalase did
not display any adverse side eﬀects, but rather a decrease
in a select group of age-related pathologies [63]. Induced
mutations in genes encoding subunits for complex II have
been demonstrated to result in increased production of O
·−
2
and H2O2 in hamster ﬁbroblasts. The increased production
of ROS was cooccurring with an increase of aneuploidy
that could be reversed by expression of complex II subunits
without mutations [59]. This led the authors to augment
that the increase of mitochondria-produced ROS resulted in
genomic instability.
5. Mitochondrial ROS Functions as
Second Messenger Molecules
Despite having been described mainly as a detrimental
byproduct of oxidative phosphorylation for more than 50
years, it has become evident that certain types of ROS
function as second messengers under subtoxic concentra-
tions. As such, ROS has been demonstrated to regulate
gene expression by controlling transcription factors and to
aﬀect protein activity by regulating kinases and phosphatases
as reviewed by Weinberg and Chandel [6]. The regulative
eﬀects of ROS are exerted through their redox potential.
As an example, several ROS sensitive molecules contain
cysteine rich proteins, in which ROS-induced oxidation can
result in formation of disulﬁde bonds in the same molecule
or between two cysteine rich molecules. The formation of
disulﬁdebondscanthereforeleadtoconformationalchanges
of a molecule or result in the dimerizations of two or more
molecules, thereby modulating activation and activity of the
molecules [64].
Molecules that are regulated by ROS have been demon-
stratedtobeinvolvedincellsurvival,cellcyclecontrol,apop-
tosis, diﬀerentiation, and several stress responses. Abnormal
signaling elicited by aberrant ROS production can therefore
aﬀect essential pathways of the cell, potentially initiating an
incorrectcellularresponsetoagivensituation,increasingthe
risk of senescence or tumorigenesis [6, 65]. Mitochondria-
p r o d u c e dR O Sh a v eb e e nd e m o n s t r a t e dt oa ﬀect the tran-
scription factor hypoxia-inducible factor 1 (HIF-1). HIF-1
is a heterodimer consisting of the constitutively expressed
subunit HIFβ and the oxygen sensitive subunit HIF-1α.
Upon expression HIF-1α is marked by ubiquitination and
subsequent degraded by the proteasome [66]. However,
an increased production of mitochondrial ROS has been
demonstrated to stabilize HIF-1α, allowing the subunit
to dimerize with HIFβ and forming the active nuclear
transcription factor. Active HIF-1 is known to regulate
the expression of glycolytic enzymes, the angiogenic factor
VEGF and aﬀect pathways promoting apoptosis [67–69]
and aberrant activity of HIF-1 has been correlated with
tumorigenesis as reviewed by Weinberg and Chandel [6].
Furthermore, loss of HIF-1α has been demonstrated to
accelerate premature cellular senescence in mice [65].
Mitogen-activated protein kinases (MAPK) are a super-
family of serine/threonine protein kinases that function
as signal transducers that propagate stimuli from growth
factors and a wide variety of cellular and extracellular
stresses [70] .T h eM A P K sa r ec r i t i c a lf o rc o r r e c tr e g u l a -
tion of gene expression, cell cycle progression, apoptosis,
and other cellular activities in response to these stimuli.
Mitochondria-produced ROS has been demonstrated to
induce phosphorylation and thereby activation of the p38
MAPK in cardiomyocytes [71]. Furthermore, the ERK1/2
MAPK is activated by exogenously added H2O2 [72] and in
eosinophils this activation is inhibited if the cells are treated
withrotenone,aninhibitorofcomplexIoftheETC[73].The
authors interpreted this to the importance of mitochondrial
respiration in activation of ERK1/2, however, rotenone is
demonstrated to induce the production of mitochondrial
ROS [74], and it is therefore possible that mitochondrial
ROS rather than mitochondrial respiration is the eﬀector
of the ERK1/2 regulation. MAPKs are critical for correct
cellular response to a variety of stimuli including mitogenic
factors and stresses, and concurrently aberrant function and
regulation of p38 MAPK and ERK1/2 has been correlated4 Journal of Aging Research
with both senescence, misregulation of apoptosis, and tumor
initiation [75–77].
HIF-1, p38 MAPK, and ERK1/2 constitute a nonex-
haustive list of biological molecules regulated either directly
or indirectly by mitochondria-produced ROS. The purpose
of this regulation is most likely for the cell to react upon
oxygen availability for oxidative phosphorylation, energetic
yield, and to respond to increased oxidative load and
mitochondrial stresses. As such, the targets of this regulation
are therefore involved in critical cellular pathways, and it
is no surprise that the majority of pathways that can be
regulated by mitochondrial ROS have been correlated with
cancer and senescence upon deregulation.
An abnormal production of mitochondrial ROS can
therefore elicit detrimental eﬀects on the cell, causing both
oxidative damages on cellular components and most likely,
an incorrectly regulated second messenger aﬀecting critical
cellular pathways.
6. MitochondrialRegulation of
the Nuclear Epigenome
Mitochondrial dysfunctions invoke mitochondria-to-
nucleus retrograde responses in human cells [78]. Cells
devoid of functional mitochondria (ρ0) are useful in studies
aiming to gain insight into the possible role of mitochondria
in regulating or being associated with the epigenetic
alterations of the nuclear genome, either gene speciﬁc or
genome wide, particularly at the level of DNA methylation.
It has been shown that depletion of the mitochondrial
genome results in aberrant methylation of promoter CpG
islands (high CG rich regions) normally unmethylated in
the parental cell line. Conversely Smiraglia et al. [79]h a s
shown that, at speciﬁc loci, the 51 UTR comprising a CpG
island was partially hypomethylated in ρ0 cells compared to
the parental cell line in which this region was completely
hypermethylated. It was suggested that the partial loss of
genomic DNA methylation could be associated with the loss
of mtDNA and mitochondrial function. Repletion of wild-
type mitochondria in ρ0 cells (mtDNA deﬁcient) resulted in
the partial re-establishment of some methylation proﬁles to
the original parental state. Accordingly, this study provides
an interesting depiction of the possible role of mitochondria
in establishing or maintaining genomic (nuclear) DNA
methylation. Interestingly, increasing evidence is emerging
onaninterdependentrelationshipbetweenthemitochondria
and the nuclear genome. It is well established that expression
of nuclear genomic DNA is regulated by epigenetic factors,
and consequently, an understanding of how mitochondria
regulate nuclear epigenetics is of great importance.
7.mtDNA andApoptosis
Mitochondria play a central role in initiation of the intrinsic
pathway of apoptosis by releasing mitochondrial proteins,
which normally reside in the intermembrane space, into the
cytosol. This triggers assembly of the apoptosome and acti-
vation of procaspase-9, leading to a cascade of events which
ultimately leads to cell death. Several studies have indicated
that mtDNA mutations are associated with mitochondrial
induced apoptosis in aging mouse models. It has been
demonstrated that a genetically engineered mouse model
expressing proofreading-deﬁcient mitochondrial DNA poly-
merase gamma accumulate mtDNA mutations and display
a premature aging phenotype [23]. It was further demon-
strated that cleaved caspase-3 levels increased with aging in
v a r i o u so r g a n so ft h em o u s em o d e l ,s u g g e s t i n gi n c r e a s e d
apoptotic activity [23]. Furthermore, Hiona et al. [80]
demonstrated an increased level of mitochondria-elicited
apoptosis in muscle tissue of the same mouse line by observ-
ing increased caspase-9 activity and a signiﬁcant positive
correlation between caspase-9 and caspase-3 activity. The
increased level of apoptosis was accompanied by a reduction
in the mitochondrial membrane potential [80]. Reduction
in the mitochondrial membrane potential has been demon-
strated to aﬀect the mitochondrial matrix condensation in
vitro, and thus the release of proapoptotic cytochrome c into
the cytosol [81]. It has also been demonstrated that aging
human colonic cells displaying respiratory chain deﬁciency
have a signiﬁcant higher apoptotic frequency compared to
normal human colonic cells [82], indicating that respiratory
deﬁciency induces apoptosis. However, Hiona et al. [80]
demonstrated that mtDNA mutations in the mouse model
of their study caused no change in activity of the ETC com-
plexes or ROS production, however, they did ﬁnd a marked
decrease in ETC complexes and ATP production, suggesting
thataccumulationofmtDNAmutationsassociatedwithETC
dysfunction and altered membrane potential may lead to
activation of the intrinsic apoptotic pathway. Thus these
studies indicate a link between increased apoptosis and
aging.
8. Mitochondrial Dysfunction and
the Cytosolic Nucleotide Metabolism
Rate-limiting steps of the metabolism of cytosolic ribonu-
cleotides and deoxyribonucleotides take place in the mito-
chondria and can be aﬀected by the ﬁtness of the organelle as
reviewed by Desler et al. [83]. In accordance, several studies
have demonstrated a correlation between mitochondrial
dysfunctions aﬀecting the ETC and aberrant synthesis of
cytosolic ribonucleotides and deoxyribonucleotides [78, 84,
85]. Deoxyribonucleotides are exclusively destined for DNA
synthesis in the form of deoxyribonucleotide triphosphates
(dNTP), but ribonucleotides have a multitude of roles in
RNA synthesis in the form of ribonucleotide triphosphates
( r N T P ) ,a sc h e m i c a lt r a n s p o r t e r si nf o r mo fA T Pa n di n
the form of basic second messenger molecules. Disrup-
tion of the intracellular levels of deoxyribonucleotides or
ribonucleotides is unfavorable as imbalance of the dNTP
pools can induce a variety of genetic changes such as base
substitutions, frameshift mutations, delay of replication fork
progression, and DNA replication as well as increase in the
frequency of fragile sites [86–91]. Decreased levels of rNTP
poolsinhibitRNAsynthesis,likelybyinhibitingtheinitiation
frequency of RNA polymerase I, and thereby inhibiting theJournal of Aging Research 5
synthesis of rRNA [92]. Furthermore, inhibition of purine
and pyrimidine synthesis induces a p53-mediated cell cycle
arrest and inhibits cell proliferation, ultimately leading to
increased cytotoxicity [93–96].
The de novo synthesis of pyrimidines is directly linked
to the ETC by the ﬂavoenzyme dihydroorotae dehydroge-
nase (DHODHase). DHODHase catalyzes the conversion
of dihydroorotate to orotate by oxidation. Subsequent cat-
alytic steps convert orotate into uridine monophosphates
that can be further converted to UTP and CTP, and
ultimately, dTTP and dCTP, respectively. DHODHase is
located in the inner membrane of the mitochondria with
the active site facing the inner membrane [2]. DHODHase
is functionally connected to the ETC by a ﬂavin prosthetic
group that couples dihydroorotate oxidation to respiratory
ubiquinone reduction [3]. From ubiquinol, the ﬂow of
electrons continues through the ETC. Leﬂunomide and
brequinar are inhibitors of DHODHase that bind to the
quinone-binding site, thereby blocking interaction between
ubiquinone and the ﬂavin prostethic group of DHODHase
[97]. Treatment of human lymphocytes with leﬂunomide or
brequinar arrests the cells in G1 phase and inhibits both
RNA and DNA synthesis [98–100]. The inhibitory eﬀects
are suppressed by addition of uridine which can be salvaged
to UMP, where by the de novo synthesis of pyrimidines
is bypassed. Treating the human leukemic cell line CCRF.
CEM with leﬂunomide or brequinar cause a signiﬁcant
reduction in the levels of CTP and UTP, while the levels
of purine nucleotides remain unaﬀected by leﬂunomide but
increasedbybrequinar[101].Furthermore,ourunpublished
data indicate that a leﬂunomide mediated inhibition of
DHODHase in a human cervical cancer cell line results
in decreased levels of dTTP and dCTP (Data not shown).
Together these results demonstrate the importance of the
activity of DHODHase for cytosolic levels of pyrimidine
nucleotides. It has been suggested that any dysfunction of
the ETC; lack of oxygen, presence of inhibitors, or mutations
of complex III and IV, would entail impairments of the de
novo UMP synthesis, and a subsequent decrease in the de
novo synthesis of cytosolic nucleotides [78, 85]. In support
of this argument it has been demonstrated that a chemical
inhibition of the ETC causing a buildup of ubiquinol has an
inhibitory eﬀect on DHODHase [85]. Inhibition of the ETC
caused by dysfunctional ETC subunits encoded by mutated
mtDNA is therefore likely to have an eﬀect on the activity
of DHODHase. Treatment of cells with chloramphenicol
inhibits mitochondrial protein synthesis, and mimics an
mtDNA-inducedmitochondrial dysfunction,impairing ETC
activity. In chick embryo cells, treatment with chloram-
phenicol was demonstrated to inhibit DHODHase activity
and cell growth [102]. Growth inhibition was reversed by
addition of pyrimidines to the growth media. This indicates
that mitochondrial dysfunction aﬀecting the ETC has an
inhibitory eﬀect on DHODHase activity that is comparable
to inhibition with leﬂunomide or brequinar. This conclusion
is substantiated by the fact that cultured mammalian cells
devoidofmtDNAareauxotrophicforpyrimidines,andmust
be routinely grown in the presence of a uridine supplement
[103].
In summary, the DHODHase links cytosolic nucleotide
metabolism with the ETC. Inhibition of DHODHase or the
ETChasbeendemonstratedtodecreasethelevelsofcytosolic
pyrimidines. It is possible that an inhibition of the ETC
induced by damaged ETC subunits encoded by mutated
mtDNA can cause an imbalance of cytosolic nucleotides,
which in turn can induce detrimental genetic changes that
are also apparent in tumor formation and aging.
9. Conclusion
For the better half of a century, both aging and cancer
formation have been associated with divergent mitochon-
drial function. Since ﬁrst suggested, the correlation between
mitochondrial dysfunctions and aging and cancer has been
d e b a t e da sm e r e l ys y m p t o m so fa g i n ga n dc a n c e r .H o w e v e r ,
with the generation of mouse lines containing a mtDNA
mutator phenotype [22, 23] and with the usage of cybrid
mechanisms in cell cultures [30–33], it has been demon-
strated that mtDNA aberrations can be correlated with at
least certain aspects of aging and cancer progression. In
this paper we have described diﬀerent immediate eﬀects of
mtDNAaberrations,andtheirpotentialroleininducingpre-
mature aging, or promote tumor progression. These eﬀects
encompass (1) altered mitochondrial production of ROS,
(2) mitochondrial regulation of the nuclear epigenome, (3)
mitochondrial initiation of apoptosis, and (4) mitochondria
induced inhibition of de novo synthesis of rNTP and dNTP
(see Figure 1). Where 1, 3, and 4 can be directly linked to
the mtDNA aberrations and their eﬀect on the ETC, the
link between mitochondria and regulation of the nuclear
epigenome is unknown and likely multifaceted. All of the
eﬀects have been correlated to either cellular senescence or
organismal premature aging and cancer progression. Even
though, all the described mechanisms can be related to
aging and cancer, the eﬀect exerted by these mechanisms
in response to mtDNA aberrations is most likely dependent
on the type of tissue and cells exposed. For example, a
mitochondrial induced inhibition of de novo synthesis of
rNTP and dNTP will not have an adverse eﬀect on cells that
areprimarilyreliantonrNTPanddNTPproducedbysalvage
pathways. Similarly, a burst of mitochondrial ROS will have
a smaller risk of inducing cellular damage if the cell or tissue
type aﬀected has suﬃcient antioxidant defenses.
The activity and eﬃciency of the ETC and thereby the
capacity for oxidative phosphorylation is directly correlated
with the ﬁdelity of the mitochondrial genome [7, 8]. The
ﬁdelity of the mitochondrial genome is determined by a
variety of factors including the speciﬁc genome region,
the type of mutation, and the ratio between unaﬀected
and aﬀected mtDNA molecules in a mitochondrion and
in the cell. Correspondingly, ROS production is low in
mitochondria with a functional ETC and increased when
especially the mtDNA encoded subunits of complex I and
III are mutated [44, 45]. However, the ﬁdelity of the
mitochondrial genome can be compromised to a threshold
where the mtDNA-encoded peptides become overloaded
with mutations such that the ETC is unable to support an6 Journal of Aging Research
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Figure 1:OverviewofeﬀectsofmtDNAaberrationscorrelatedagingandcancerprogression.AberrantmitochondrialDNAcausesareduced
ﬁdelityoftheelectrontransportchain,whichinturncanaltertheproductionofreactiveoxygenspecies(ROS),prematurelyinitiateapoptotic
events and alter the nucleotide metabolism. An increased production of ROS can cause oxidative damage to cellular components including
nuclear DNA, while both a decrease and increase of ROS can compromise its role as a second messenger molecule, aﬀecting several cellular
mechanisms. An altered nucleotide metabolism can result in a altered production of ribonucleotides and deoxyribonucleotides increasing
the risk of inhibition of RNA synthesis and DNA mutations, respectively. Aberrant mitochondrial DNA can also alter the regulation of the
nuclear epigenome even though the mechanism responsible has not been elucidated.
electron transport. In this situation, the ETC can neither
perform oxidative phosphorylation nor produce ROS. As the
capacity for oxidative phosphorylation and the production
of mitochondrial ROS are correlated with the ﬁdelity of the
mitochondrial genome, the immediate eﬀects of mtDNA
aberrations most likely elicits their maximal destructive
eﬀects at diﬀerent points in the course of the degradation
of the mitochondrial genome. The ability of mitochondria-
produced ROS to induce oxidative damage to cellular
components are maximal in situations where the ﬁdelity
of the mitochondrial genome allows transport of electrons
through the ETC, but when electron leak is so abundant
that the cellular antioxidative defenses are saturated and
an overload of harmful ROS molecules are allowed to
form. In contrast, the role of ROS as signal molecules is
aﬀected in situations where the production is both increased
and decreased. In cases where ROS as a signal molecule
mediates a stress response, an increased production of ROS
will potentially trigger an unnecessary range of responses,
including stalling of cell cycle or initiation of apoptosis. In
contrast decreased production of ROS mediate improper
stress responses with aﬀected cells more vulnerable to a
given situation. Accordingly both an increased and decreased
level of ROS can theoretically increase the risk of senescence
or contribute to tumor initiation and progression, in light
of the second messenger role of ROS. The activity of
the DHODHase is inversely correlated with the activity of
the ETC. Therefore, the risk of a mitochondrial induced
imbalance of the cellular rNTP and dNTP pool is most
pronounced when the ETC is unable to transport electrons.
It is an important realization that aberrations of mtDNA
can induce the risk of cellular senescence, organismal
premature aging, and cancer progression through a vari-
ety of diﬀerent mechanisms, dependent on the type of
mtDNA alteration and the cell or tissue type aﬀected.
As a consequence, the mechanism linking mitochondrial
dysfunction to cancer and aging can no longer be perceived
as a simple mechanism where oxidative damage to cellular
components induced by mitochondria-produced ROS is the
mainmediator.Ratherthispathwayiscomplexandmediated
by several critical cellular events aﬀected by mitochondrial
function.
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